{"filing":{"accession_number":"0001140361-26-026506","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"ef20076710_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/ef20076710_8k.htm"},"events":[{"id":14126,"run_id":12565,"accession_number":"0001140361-26-026506","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Dr. Randal W. Scott resigned from the Board of Directors effective June 22, 2026, upon completion of his Class I director term. The resignation was not due to any disagreement with the Company.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11470,"accession_number":"0001140361-26-026506","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Dr. Randal W. Scott resigned from the Board of Directors effective June 22, 2026, upon completion of his Class I director term. The disclosure explicitly states the resignation was not due to any disagreement with the Company. This is a routine director departure at the end of a term with no controversy or material adverse implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:31:44.928302+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":14127,"run_id":12565,"accession_number":"0001140361-26-026506","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"BridgeBio held its Annual Meeting on June 22, 2026, with shareholders voting on five proposals: election of three Class I directors (James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine), advisory approval of named executive officer compensation, annual frequency of say-on-pay votes, ratification of Deloitte \u0026 Touche LLP as independent auditor, and approval of an amendment to the 2021 Stock Option and Incentive Plan increasing reserved shares by 2,000,000.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11471,"accession_number":"0001140361-26-026506","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of BridgeBio's Annual Meeting held on June 22, 2026, including voting outcomes on five proposals: election of three Class I directors (James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine), advisory approval of named executive officer compensation, frequency of future say-on-pay votes (approved for annual frequency), ratification of Deloitte \u0026 Touche LLP as independent auditor, and approval of an amendment to the 2021 Stock Option and Incentive Plan increasing shares reserved by 2,000,000. The disclosure provides vote tallies (for, against, abstentions, and broker non-votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:31:44.928302+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11470,"accession_number":"0001140361-26-026506","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Dr. Randal W. Scott resigned from the Board of Directors effective June 22, 2026, upon completion of his Class I director term. The disclosure explicitly states the resignation was not due to any disagreement with the Company. This is a routine director departure at the end of a term with no controversy or material adverse implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:31:44.928302+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-06-26"},{"id":11471,"accession_number":"0001140361-26-026506","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of BridgeBio's Annual Meeting held on June 22, 2026, including voting outcomes on five proposals: election of three Class I directors (James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine), advisory approval of named executive officer compensation, frequency of future say-on-pay votes (approved for annual frequency), ratification of Deloitte \u0026 Touche LLP as independent auditor, and approval of an amendment to the 2021 Stock Option and Incentive Plan increasing shares reserved by 2,000,000. The disclosure provides vote tallies (for, against, abstentions, and broker non-votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:31:44.928302+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-06-26"}]}